https://www. theguardian.com/media/2026/aug /22/deadly-tiktok-motorway-driving-trend-horrifies-ireland

https://www.

FDA approves breakthrough pancreatic cancer drug

The FDA approved Revolution Medicines' daraxonrasib on August 26–27, 2026, a landmark pancreatic cancer treatment that nearly doubled average survival times in trials; the drug is priced above $475,000 annually.

A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs

FDA approves breakthrough drug for pancreatic cancer treatment

FDA approves Revolution Medicines pancreatic cancer drug

Revolution Medicines received FDA approval on August 26, 2026, for daraxonrasib (Rasonque), a once-daily pill that blocks RAS protein variants driving pancreatic cancer growth.

FDA approves Rasonque for metastatic pancreatic cancer

The Food and Drug Administration approved Rasonque (daraxonrasib), a once-daily targeted therapy by Revolution Medicines, on August 26, 2026 for adults with metastatic pancreatic adenocarcinoma. The drug represents the first in its class for this indication.